Desde 500€ puedes invertir en Biocross a través de Blockchain
the life expectancy and quality of life of individuals with neurodegenerative diseases
through the design of innovative diagnostic systems.
and non-invasive diagnostic tools that can be used
at any stage of the disease.
Early diagnosis
Reliable
Non-invasive
Our goal
To provide neurologists with an integrated diagnostic solution that can be applied to any stage of the disease, including the earliest, asymptomatic phase.
Benefits
- Reduced cost of AD risk-assessment and diagnosis.
- More widespread testing thanks to simpler, more readily available diagnostic methods.
- Improved diagnosis, through earlier detection and differentiation of distinct dementia types.
- Simplified diagnosis through leveraging of existing laboratory equipment.
- Improved patient experience and safety.
The e4Risk® is a non-genetic, cost-effective, and highly reliable method to detect the presence of the ApoE4 protein in human blood plasma using high-throughput chemical analysis.
The AD Dementia test is a multiparametric test that combines the detection and quantification of up to 9 metabolites or proteins in a plasma sample. The input of these measurements into an algorithm provides an accurate diagnosis and classifies the patient as either Alzheimer´s disease or frontotemporal dementia.
The Degenerative dementia test is based on the detection and quantification of up to 7 blood biomarkers that are specifically altered in patients affected by neurodegeneration due to FTD or AD. The DD test is conceived as a “screening” tool for use in clinical practice.
Biocross: a multiparametric method for the blood-based diagnosis of Alzheimer’s disease
Early diagnosis a key tool in the fight against disease. It is thus essential that currently available tools are continually improved. Biocross has defined 3 main objectives that will guide the direction of this project.
Approval of a clinical study for the identification in blood of markers.
Biocross announces approval of a clinical study for the identification in blood of markers for the diagnosis of Alzheimer’s disease using a multiparametric test – September 2011.
The Junta’s venture capital fund regains momentum with investment in biotechnology.
After nearly six months of inactivity, venture capital firm Ade Sodical, owned by the Junta de Castilla y Leon, has been reactivated with an investment in Biocross.
If you have any questions or comments, we will be pleased to attend you
Avda. Francisco Vallés, 8
47151 Boecillo (Valladolid) - Spain
+34 983 54 98 96